Race/ethnicity-specific disparities in hepatocellular carcinoma stage at diagnosis and its impact on receipt of curative therapies

Journal of Clinical Gastroenterology

Volumn 50, Issue 5, 2016, Pages 423-430

  Ha, John ^a   Yan, Melissa ^a   Aguilar, Maria ^a   Tana, Michele ^b   Liu, Benny ^a   Frenette, Catherine T ^c   Bhuket, Taft ^a   Wong, Robert J ^a  

^a HIGHLAND HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS GREEN HOSPITAL   (United States)

Author keywords

Liver cancer; Liver transplantation; SEER; Surgical resection; UNOS

Indexed keywords

ADULT; AGED; ARTICLE; ASIAN; BLACK PERSON; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CAUCASIAN; COHORT ANALYSIS; DATA BASE; DISEASE COURSE; FEMALE; HISPANIC; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; TREATMENT INDICATION; TUMOR VOLUME; UNITED STATES; ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; EPIDEMIOLOGY; ETHNIC GROUP; ETHNOLOGY; HEALTH CARE DISPARITY; INCIDENCE; LIVER NEOPLASMS; PATHOLOGY; STATISTICS AND NUMERICAL DATA;

AGED; CARCINOMA, HEPATOCELLULAR; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HEALTHCARE DISPARITIES; HUMANS; INCIDENCE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM STAGING; SEER PROGRAM; UNITED STATES;

EID: 84947788556     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000448     Document Type: Article

References (38)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
4. Hung TH, Lay CJ, Chang CM, et al. The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy. Epidemiol Infect. 2013;141:2671-2678.
5. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-1127.
6. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767-1775.
7. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol. 2010;37:202-215.
8. Wong RJ, Devaki P, Nguyen L, et al. Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for End-stage Liver Disease score. Clin Gastroenterol Hepatol. 2014;12:1534-1540. e1531.
9. Surveillance E, and End Results (SEER) Program (http://www.seer.cancer.org) SEER∗Stat Database: SEER∗Stat 8.0. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014. November 2013 submission. site.
10. Adamo MDL, Ruhl J. 2014 SEER Program Coding and Staging Manual. Bethesda, MD: National Cancer Institute. 20850-297652014.
11. Wong RJ, Corley DA. Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci. 2009;54:2031-2039.
12. Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008;121:525-531.
13. Altekruse SF, Henley SJ, Cucinelli JE, et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109: 542-553.
14. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27: 1485-1491.
15. Wong RJ, Devaki P, Nguyen L, et al. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the surveillance, epidemiology, and end results registry. Liver Transpl. 2014;20:528-535.
16. Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc. 2006;98:1934-1939.
17. Davila JA, El-Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: a populationbased study. Clin Gastroenterol Hepatol. 2006;4:104-110. Quiz 104-105.
18. Sarkar M, Stewart S, Yu A, et al. Hepatocellular carcinoma screening practices and impact on survival among hepatitis Binfected Asian Americans. J Viral Hepat. 2012;19:594-600.
19. Mathur AK, Osborne NH, Lynch RJ, et al. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg. 2010;145: 1158-1163.
20. Wang J, Wang FW. Refusal of cancer-directed surgery strongly impairs survival of patients with localized hepatocellular carcinoma. Int J Surg Oncol. 2010;2010:381795.
21. Fiscella K, Franks P, Gold MR, et al. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA. 2000;283:2579-2584.
22. Yu L, Sloane DA, Guo C, et al. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol. 2006;4:355-360.
23. Guidry JJ, Aday LA, Zhang D, et al. Cost considerations as potential barriers to cancer treatment. Cancer Pract. 1998;6:182-187.
24. Eckhoff DE, McGuire BM, Young CJ, et al. Race: a critical factor in organ donation, patient referral and selection, and orthotopic liver transplantation? Liver Transpl Surg. 1998;4: 499-505.
25. Moylan CA, Brady CW, Johnson JL, et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA. 2008;300:2371-2378.
26. Reid AE, Resnick M, Chang Y, et al. Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transpl. 2004;10:834-841.
27. Siegel AB, McBride RB, El-Serag HB, et al. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol. 2008;103:120-127.
28. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-562.
29. O'Leary JG, Landaverde C, Jennings L, et al. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol. 2011;9:700-704. e701.
30. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38:420-427.
31. Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682-689.
32. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608-612.
33. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-121.
34. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-300.
35. El-Serag HB, Kramer J, Duan Z, et al. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014;109: 1427-1435.
36. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547-555.
37. De Luna WSD, Ahmed A, Ha BY, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant. 2009;9:1158-1168.
38. Ha BY, Ahmed A, Sze DY, et al. Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion. Aliment Pharmacol Ther. 2007;26:839-846.